Sporadic Alzheimer's disease is characterised by cognitive impairments and associated with cerebrometabolic anomaly and dementia which are burdensome for the old age population and their caregivers worldwide. A safe and effective treatment is essentially required for its prevention and cure. γ-Oryzanol (OZ) is reported for anti-oxidative, anti-inflammatory, anticancer, anti-hyperlipidemic, and anti-diabetic effects in various preclinical studies. In silico studies showed similar binding interactions with acetylcholinisterase like Donepezil (DONO). In vitro DPPH assay, AchE activity inhibition assay and cell viability assay on SH-SY5Y cell line confirmed that OZ has good free radical scavenging and cholinesterase inhibitory activity as well as safety profile. OZ was evaluated in vivo for its effect in streptozotocin (STZ) induced sporadic Alzheimer's disease in rats. Maze tests reflected improvement in spatial cognitive behavior indicated by reduction in working memory and reference memory error. OZ showed anti-AchE, anti-inflammatory and antioxidative effects. OZ showed effective anti-proinflammatory effects in cerebral milieu as indicated by significant reduction in active glial cells and found to improve synaptic connectivity. Thereby OZ reflected protection of the cerebral architecture against STZ induced damage. Thus, OZ exhibits its candidature as a therapeutic moiety to improve cognitive behavior in neurodegenerative disorders.

Nirma University Institute of Pharmacy Department of Pharmacology Gujarat India

Citace poskytuje Crossref.org

Literatura